Technical Analysis for RLAY - Relay Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 39.9 -0.92% -0.37
RLAY closed down 0.92 percent on Friday, October 23, 2020, on 21 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Flat
Historical RLAY trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Support Bullish 0.00%
Multiple of Ten Bearish Other 0.00%
Crossed Above 50 DMA Bullish -0.92%
180 Bullish Setup Bullish Swing Setup -0.92%
Multiple of Ten Bullish Other -0.92%
50 DMA Resistance Bearish 4.23%
MACD Bearish Centerline Cross Bearish 4.23%
Multiple of Ten Bearish Other 4.23%
20 DMA Resistance Bearish 2.33%
Older End-of-Day Gignals for RLAY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 2 days ago
50 DMA Support 2 days ago
Down 3% 2 days ago
Down 2 % 2 days ago
Fell Below 50 DMA 2 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Drug Discovery Enzymes Tyrosine Kinase Receptors Advanced Solid Tumors Tyrosine Kinase C Met Fibroblast Growth Factor Receptor 2 Metastatic Solid Tumors

Is RLAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 49.89
52 Week Low 32.56
Average Volume 369,283
200-Day Moving Average 0.00
50-Day Moving Average 39.25
20-Day Moving Average 40.96
10-Day Moving Average 39.77
Average True Range 3.20
ADX 19.89
+DI 20.69
-DI 18.69
Chandelier Exit (Long, 3 ATRs ) 35.88
Chandelier Exit (Short, 3 ATRs ) 45.09
Upper Bollinger Band 45.16
Lower Bollinger Band 36.76
Percent B (%b) 0.37
BandWidth 20.49
MACD Line -0.15
MACD Signal Line 0.18
MACD Histogram -0.334
Fundamentals Value
Market Cap 3.59 Billion
Num Shares 90 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -40.30
Price-to-Sales 0.00
Price-to-Book 10.52
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 43.67
Resistance 3 (R3) 43.75 42.57 43.04
Resistance 2 (R2) 42.57 41.61 42.53 42.83
Resistance 1 (R1) 41.24 41.02 40.65 41.16 42.62
Pivot Point 40.06 40.06 39.77 40.02 40.06
Support 1 (S1) 38.73 39.10 38.14 38.65 37.18
Support 2 (S2) 37.55 38.51 37.51 36.97
Support 3 (S3) 36.22 37.55 36.76
Support 4 (S4) 36.14